Navigation Links
EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
Date:10/29/2008

Serono an excellent strategic partner to bring the value of tesamorelin to patients in need, post approval," commented Mr. Yves Rosconi, President and CEO of Theratechnologies.

Tesamorelin is a growth hormone-releasing factor analogue with therapeutic potential in a variety of anabolic and lipolytic indications and is in the final stages of its second Phase 3 clinical trial to assess the safety and efficacy when used to reduce visceral adipose tissue in HIV patients with lipodystrophy. The purpose of the study is to confirm the results of the first Phase 3 study, concluded in October 2007.

Terms of the Agreement

Under the terms of the agreement, Theratechnologies will receive an upfront payment of US$30 million which includes a license fee of US$22 million and an equity investment of US$8 million in Theratechnologies common stock at a price of $3.67USD [$4.73CAD] per share by Merck KGaA, providing Merck KGaA a 3.6% ownership in Theratechnologies. Theratechnologies may receive up to US$215 million in total payments, including the upfront payment and payments based on the achievement of certain development, regulatory and sales milestones. Theratechnologies will be entitled to receive increasing royalties on annual net sales of tesamorelin in the US.

Theratechnologies will be responsible for conducting research and development for additional indications. EMD Serono will have the option to co-develop and commercialize additional indications for tesamorelin in the US. EMD Serono will equally share in the development costs related to such additional indications if it exercises its option. Theratechnologies will, in such case, also have the right, subject to EMD Serono's agreement, to opt to co-promote such additional indications.

Consummation of this transaction is subject to customary closing conditions and notification to, and regulatory review by, the US Federal Trade Commission and US Department of Justice under the U.S. Hart-Scott-
'/>"/>

SOURCE EMD Serono, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
2. InterPage L.P. Announces New Enhancements to Enterprise 101 Messaging Solution
3. ATS Medical Announces Third Quarter 2008 Earnings Release Date and Conference Call
4. Animal Health International, Inc. Announces Its First Quarter Fiscal Year 2009 Earnings Release Date and Conference Call Information
5. Sonic Innovations Announces Results for Third Quarter 2008
6. WellPoint Announces Appearances at Upcoming Conferences
7. Beckman Coulter Announces Third Quarter 2008 Results
8. Align Technology Announces Third Quarter Fiscal 2008 Results
9. Rochester Medical Announces Fourth Quarter 2008 Earnings Conference Call November 6, 2008
10. IRIDEX Announces Third Quarter 2008 Conference Call and Release Date
11. Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The Advocator Group, LLC is ... Foundation for Suicide Prevention’s (AFSP) Out of the Darkness ... organization that hosts hundreds of community walks throughout the ... used to help understand and prevent suicide through not ... well. , The Advocator Group shares this passion ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... Maryland, USA (PRWEB) October 20, 2014 ... to track interventions? Here comes a wonderful app Metassessor ... mobile app development company helped its client “Intervention ... more efficiently. The app is designed for iOS 4.3 ... iPod touch. This app is optimized for iPhone 5. ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... BETHESDA, Md. (May 1, 2009) − Medical science took ... that, at least temporarily, perform the function of vital ... machine and renal dialysis, require the blood to be ... known as extracorporeal circulation (EC) and have provided critical ...
... in the May 1 issue of the journal SLEEP ... more likely to suffer from significant sleep disturbances at 2 ... of the study are of particular importance, as sleep disturbances ... depression in childhood. , Results indicate that infants ...
... who are wounded in combat as the result of a ... develop an abnormality known as heterotopic ossification. In this condition, ... near a fracture or other bone injury. New research conducted ... helping to pave the way for a better understanding of ...
... President pro Tem Darrell Steinberg (D-Sacramento) today announced ... Autism (ASD) & Related Disorders which will build ... the three-year California Legislative Blue Ribbon ... by Steinberg and ended in November 2008. ...
... (NYSE: BKD ) announced today that it plans to ... on Wednesday, May 6, 2009. The Company has also scheduled ... 2009 at 10:00 AM ET. The conference call can be ... 634-9069 (from outside of the U.S.) ten minutes prior to the ...
... news updates, features live, daily call-in shows hosted by world-class ... Ten Swine Flu FAQs at www.sirius.com/doctorradio , NEW ... (Nasdaq: SIRI ) has begun regular live updates ... health and medical channel powered by NYU Langone Medical Center. ...
Cached Medicine News:Health News:Chemical can reproduce complications for some patients 2Health News:Chemical can reproduce complications for some patients 3Health News:Chemical can reproduce complications for some patients 4Health News:Chemical can reproduce complications for some patients 5Health News:Maternal depression is associated with significant sleep disturbance in infants 2Health News:Injured Marines at risk for abnormal bone growth 2Health News:Steinberg Announces Senate Select Committee on Autism and Related Disorders 2Health News:Brookdale Announces First Quarter 2009 Release and Earnings Call 2Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 2Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 3Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 4Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 5Health News:Swine Flu Epidemic Reported on by Doctors on SIRIUS XM's Doctor Radio Channel 6
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma ... it will report its third quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:10/19/2014)... Große Pharmafirmen werden oft ... dabei ist, dass große Pharmafirmen nicht willens sind, ... Es war deshalb nicht einfach, diesen ... mehr, dass es uns gelungen ist! Wir haben ... - mit einem Vorbehalt - einige haben uns ...
(Date:10/17/2014)... , Oct. 17, 2014 With the ... Affairs function has come across several challenges in ... and managing globalization.  The ... is dedicated to providing benchmarking and best practices ... Consortium is a service composed of three stages: ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Inc. (Nasdaq: AUXL ) today announced that ... 31st Annual Health Care Conference during March 7-9, 2011 ... Chief Financial Officer, is scheduled to present an overview ... a.m. ET on Wednesday, March 9, 2011.   ...
... 2, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced that, ... determination from the NASDAQ Listing Qualifications Panel (the "Panel") ... for an extension to remain listed on The NASDAQ ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 3Nile Therapeutics Receives Positive NASDAQ Panel Decision 2Nile Therapeutics Receives Positive NASDAQ Panel Decision 3
The Nine West Eyewear collection is positioned to present today's styles with a sharp, edgy contemporary attitude tied into a clean design element....
Inquire...
Inquire...
Inquire...
Medicine Products: